Assembly Biosciences opened lower at $22.10, compared with its previous close of $22.37. In the last trading session, the stock traded between $19.84 and $22.15. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Assembly Biosciences is now worth
$ 58.38
Resulting in a loss of
$ 41.62 (41.62%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-2.12 (-9.49%)
Day High
$22.15
Day Low
$19.84
Day Open
$22.10
Prev Close
$22.37
Volume
4,67,704
1W Return
1.98%
1M Return
-11.36%
3M Return
-25.40%
6M Return
-33.42%
1Y Return
-38.89%
Fundamentals
Market Cap ($ Mn)
412
PE Ratio
32.72
PB Ratio
2.21
PEG Ratio
-
ROE
-6.54%
ROCE
-10.96%
EPS (TTM)
$-0.19
Investment Returns
1 Week
1.98%
1 Month
-11.36%
3 Months
-25.40%
6 Months
-33.42%
9 Months
-26.00%
Financials
Quarterly
All values in $ Mn
7.4
Dec 24
9.4
Mar 25
9.6
Jun 25
10.8
Sep 25
42.5
Dec 25
13.4
Jun 26
Updates
5Oct
Assembly Bio to present positive ABI-6250 Phase 1a data at AASLD 2026
Assembly Biosciences presents ABI-6250 Phase 1a data at AASLD 2026. Drug showed favorable safety with no serious adverse events. Dose-dependent bile acid increases confirm NTCP target engagement. Phase 2 trials for HDV start Q4 2026; PBC/PSC trials start Q1 2027.
1mo ago
11Sep
Assembly Biosciences to present at H.C. Wainwright conference
Assembly Biosciences management to present at H.C. Wainwright & Co. 28th Annual Global Investment Conference. Presentation scheduled for September 16, 2026 at 8:30 am Eastern Time. Live webcast and replay available via the company's investor relations website. Company develops small-molecule therapeutics for viral and liver diseases.
2mo ago
14Aug
Assembly Biosciences Q2 Results: Net loss narrows to $3.9M, revenue up
Assembly Biosciences reported a Q2 2026 net loss of $3.9 million, down from $10.2 million YoY, aided by $13.4 million in revenue and $2.5 million in interest income. Cash stands at $320.4 million. Pipeline updates include ABI-6250 expansion into cholestatic liver diseases and GS-1179 Phase 2 initiation plans with Gilead.
3mo ago
15Jun
Mizuho raises Assembly Biosciences price target to $45
Mizuho analyst Salim Syed maintained an Outperform rating on Assembly Biosciences and raised the stock's price target from $40 to $45.
